Cargando…

Risk of pneumonia with inhaled corticosteroid/long-acting β2 agonist therapy in chronic obstructive pulmonary disease: a cluster analysis

BACKGROUND: Pneumonia poses a significant risk in patients with moderate to severe chronic obstructive pulmonary disease but data are limited on the disease phenotypes most susceptible to pneumonia. METHODS: Cluster analysis using a data-driven recursive partitioning algorithm was employed using bas...

Descripción completa

Detalles Bibliográficos
Autores principales:	DiSantostefano, Rachael L, Li, Hao, Hinds, David, Galkin, Dmitry V, Rubin, David B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4019612/ https://www.ncbi.nlm.nih.gov/pubmed/24855350 http://dx.doi.org/10.2147/COPD.S60498

Ejemplares similares

Identification of responders to inhaled corticosteroids in a chronic obstructive pulmonary disease population using cluster analysis
por: Hinds, David R, et al.
Publicado: (2016)

Risk of Pneumonia with Inhaled Corticosteroid versus Long-Acting Bronchodilator Regimens in Chronic Obstructive Pulmonary Disease: A New-User Cohort Study
por: DiSantostefano, Rachael L., et al.
Publicado: (2014)

Which patients with chronic obstructive pulmonary disease benefit from the addition of an inhaled corticosteroid to their bronchodilator? A cluster analysis
por: DiSantostefano, Rachael L, et al.
Publicado: (2013)

Correction to: Effect of inhaled corticosteroid particle size on asthma efficacy and safety outcomes: a systematic literature review and meta-analysis
por: El Baou, Céline, et al.
Publicado: (2017)

Estimating Inhaled Corticosteroid Exposure from Short-Acting β(2)-Agonist–Inhaled Corticosteroid Rescue
por: Lugogo, Njira, et al.
Publicado: (2023)

Effect of Adding Inhaled Corticosteroid to Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist Therapy Among Patients With Chronic Obstructive Pulmonary Disease
por: Yuasa, Mizuki, et al.
Publicado: (2021)

Management of Asthma and Chronic Obstructive Pulmonary Disease with Combination Inhaled Corticosteroids and Long-Acting β-Agonists: A Review of Comparative Effectiveness Research
por: Mapel, Douglas W., et al.
Publicado: (2014)

Therapeutic preferences and factors determining the use of inhaled corticosteroids with long-acting β(2)-agonists in patients with asthma and chronic obstructive pulmonary disease
por: Olszanecka-Glinianowicz, Magdalena, et al.
Publicado: (2020)

Effects of Roflumilast on Patients with Chronic Obstructive Pulmonary Disease Treated with Inhaled Corticosteroid/Long-Acting β2 Agonist: A Meta-analysis
por: Zeng, Shasha, et al.
Publicado: (2022)

Prescription Patterns of New Use of Fixed-Dose Combination Inhalers in Patients with Chronic Obstructive Pulmonary Disease: Long-Acting β2 Agonists Plus Long-Acting Muscarinic Antagonists versus Long-Acting β2 Agonists Plus Inhaled Corticosteroids
por: Liao, Pei-An, et al.
Publicado: (2023)

Role of Tiotropium in Reducing Exacerbations of Chronic Obstructive Pulmonary Disease When Combined With Long‐Acting β (2)‐Agonists and Inhaled Corticosteroids: The OUTPUL Study
por: Ferroni, Eliana, et al.
Publicado: (2016)

Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD
por: Pavord, Ian D, et al.
Publicado: (2016)

Comparison of pneumonia incidence between long-acting muscarinic antagonist and inhaled corticosteroid plus long-acting beta agonist in patients with COPD
por: Lee, Eung Gu, et al.
Publicado: (2023)

Impact of adherence to treatment with inhaled corticosteroids/long-acting β-agonists on asthma outcomes in the United States
por: Averell, Carlyne M., et al.
Publicado: (2022)

Severe exacerbation and pneumonia in COPD patients treated with fixed combinations of inhaled corticosteroid and long-acting beta2 agonist
por: Yang, Hsi-Hsing, et al.
Publicado: (2017)

Treatment with inhaled corticosteroids in chronic obstructive pulmonary disease
por: Janson, Christer
Publicado: (2020)

Prescribing of long-acting beta-2-agonists/inhaled corticosteroids after the SMART trial
por: Rottenkolber, Marietta, et al.
Publicado: (2015)

Add-on Therapy for Symptomatic Asthma despite Long-Acting Beta-Agonists/Inhaled Corticosteroid
por: Dreher, Michael, et al.
Publicado: (2018)

Inhaled corticosteroids might not increase the risk of pneumonia in patients with chronic obstructive pulmonary disease in Japan
por: Hirano, Ryosuke, et al.
Publicado: (2018)

Associated Factors of Pneumonia in Individuals with Chronic Obstructive Pulmonary Disease (COPD) Apart from the Use of Inhaled Corticosteroids
por: Lineros, Rosario, et al.
Publicado: (2023)

Low adherence to inhaled corticosteroids/long-acting β(2)-agonists and biologic treatment in severe asthmatics
por: Caminati, Marco, et al.
Publicado: (2020)

Validation of chronic obstructive pulmonary disease recording in the Clinical Practice Research Datalink (CPRD-GOLD)
por: Quint, Jennifer K, et al.
Publicado: (2014)

Lung function decline before and after treatment of World Trade Center associated obstructive airways disease with inhaled corticosteroids and long‐acting beta agonists
por: Goldfarb, David G., et al.
Publicado: (2021)

An assessment of asthma exacerbations in pediatric patients using a long-acting B2-agonist plus inhaled corticosteroid versus an inhaled corticosteroid alone
por: Alakeel, Yousif S., et al.
Publicado: (2022)

Comparative Effectiveness of Umeclidinium/Vilanterol versus Inhaled Corticosteroid/Long-Acting β(2)-Agonist in Patients with Chronic Obstructive Pulmonary Disease in a Primary Care Setting in England
por: Czira, Alexandrosz, et al.
Publicado: (2023)

The Impact of Inhaled Corticosteroids on the Prognosis of Chronic Obstructive Pulmonary Disease
por: Park, Ji Won, et al.
Publicado: (2023)

Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β(2) agonist: observational matched cohort study (PATHOS)
por: Janson, Christer, et al.
Publicado: (2013)

Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS)
Publicado: (2013)

Using Societal Values to Inform Public Health Policy During the COVID-19 Pandemic: The Role of Health Preference Research
por: DiSantostefano, Rachael L., et al.
Publicado: (2021)

Transcriptome analysis in patients with asthma after inhaled combination therapy with long-acting β2-agonists and corticosteroids
por: Liang, Ya-Ru, et al.
Publicado: (2022)

Characterisation of patients with chronic obstructive pulmonary disease initiating single-device inhaled corticosteroids/long-acting β(2)-agonist dual therapy in a primary care setting in England
por: Czira, Alexandrosz, et al.
Publicado: (2022)

Physicians’ attitudes towards combination therapy with inhaled corticosteroids and long-acting β(2)-agonists: an observational study in UK specialist care
por: Thomas, Mike, et al.
Publicado: (2011)

Inhaled Corticosteroids Increase the Risk of Pneumonia in Patients With Chronic Obstructive Pulmonary Disease: A Nationwide Cohort Study
por: Lee, Ming-Chia, et al.
Publicado: (2015)

An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease
por: Singh, Sonal, et al.
Publicado: (2010)

Inhaled Corticosteroids for Chronic Obstructive Pulmonary Disease—The Shifting Treatment Paradigm
por: Wilkie, Morven, et al.
Publicado: (2015)

Inhaled corticosteroids for chronic obstructive pulmonary disease: what is their role in therapy?
por: Tashkin, Donald P, et al.
Publicado: (2018)

Inhaled Corticosteroids in Asthma and the Risk of Pneumonia
por: Kim, Min-Hye, et al.
Publicado: (2019)

Impact of changes to reimbursement of fixed combinations of inhaled corticosteroids and long-acting β(2)-agonists in obstructive lung diseases: a population-based, observational study
por: Björnsdóttir, U S, et al.
Publicado: (2014)

A smarter way to manage asthma with a combination of a long-acting β(2)-agonist and inhaled corticosteroid
por: Selroos, Olof
Publicado: (2007)

Inhalation devices and inhaled corticosteroids particle size influence on severe pneumonia in patients with chronic obstructive pulmonary disease: a nationwide cohort study
por: Heerfordt, Christian Kjer, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_g2h6vle34c6pfrpdg6au7trrqb